Clincosm LogoSign in Get a demo

stage iiib skin melanoma

Showing 1 - 14 of 14
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Recurrent Melanoma, Stage IIIB Skin Melanoma, Stage IIIC Skin Melanoma Trial in Buffalo (Recombinant Human Hsp110-gp100

Terminated
  • Recurrent Melanoma
  • +3 more
  • Recombinant Human Hsp110-gp100 Chaperone Complex Vaccine
  • Laboratory Biomarker Analysis
  • Buffalo, New York
    Roswell Park Cancer Institute
Jul 20, 2022

Acute Myeloid Leukemia, Brain Glioblastoma, Estrogen Receptor Negative Trial in Fullerton (Best Practice, Laboratory Biomarker

Active, not recruiting
  • Acute Myeloid Leukemia
  • +66 more
  • Best Practice
  • +3 more
  • Fullerton, California
    Virginia K Crosson Cancer Center
Jan 31, 2022

Metastatic Melanoma, Stage III Mucosal Melanoma of the Head and Neck, Stage IIIA Skin Melanoma Trial in New Brunswick

Active, not recruiting
  • Metastatic Melanoma
  • +8 more
  • Aldesleukin
  • +2 more
  • New Brunswick, New Jersey
    Rutgers Cancer Institute of New Jersey
Sep 20, 2021

Stage 0 Skin Melanoma, Stage I Skin Melanoma, Stage IA Skin Melanoma Trial in New Brunswick, Charlottesville (Internet-Based

Completed
  • Stage 0 Skin Melanoma
  • +11 more
  • Internet-Based Intervention
  • +2 more
  • New Brunswick, New Jersey
  • +1 more
Apr 7, 2021

Malignant Female Reproductive System Tumor, Malignant Hepatobiliary Tumor, Partner Trial in New Brunswick (Cognitive Behavior

Completed
  • Malignant Female Reproductive System Neoplasm
  • +38 more
  • Cognitive Behavior Therapy
  • +3 more
  • New Brunswick, New Jersey
    Rutgers Cancer Institute of New Jersey
Apr 7, 2021

Recurrent Melanoma, Stage IA Skin Melanoma, Stage IB Skin Melanoma Trial in Buffalo (procedure, drug, other)

Completed
Has Results
  • Recurrent Melanoma
  • +9 more
  • Diagnostic Microscopy
  • +3 more
  • Buffalo, New York
    Roswell Park Cancer Institute
Jul 24, 2020

Stage IIA Skin Melanoma, Stage IIB Skin Melanoma, Stage IIC Skin Melanoma Trial in Rochester (biological, drug, other)

Completed
  • Stage IIA Skin Melanoma
  • +6 more
  • MART-1 Antigen
  • +2 more
  • Rochester, Minnesota
    Mayo Clinic
Jan 13, 2020

Stage IA Skin Melanoma, Stage IB Skin Melanoma, Stage IIA Skin Melanoma Trial in Columbus (recombinant interferon alfa-2b,

Completed
Has Results
  • Stage IA Skin Melanoma
  • +8 more
  • recombinant interferon alfa-2b
  • laboratory biomarker analysis
  • Columbus, Ohio
    Ohio State University Medical Center
Oct 31, 2018

Stage IIIA Skin Melanoma, Stage IIIB Skin Melanoma, Stage IIIC Skin Melanoma Trial (drug, other, biological)

Withdrawn
  • Stage IIIA Skin Melanoma
  • +3 more
  • Imatinib Mesylate
  • +2 more
  • (no location specified)
Apr 3, 2018

Recurrent Melanoma, Stage IIIA Skin Melanoma, Stage IIIB Skin Melanoma Trial in United States (biological, drug, other)

Completed
Has Results
  • Recurrent Melanoma
  • +4 more
  • Aldesleukin
  • +5 more
  • Birmingham, Alabama
  • +18 more
Nov 16, 2017

Recurrent Melanoma, Stage IIIB Skin Melanoma, Stage IIIC Skin Melanoma Trial in Philadelphia, Charlottesville (biological,

Completed
Has Results
  • Recurrent Melanoma
  • +3 more
  • Bevacizumab
  • +3 more
  • Philadelphia, Pennsylvania
  • +1 more
May 5, 2017

Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma, Anaplastic Oligodendroglioma Trial in Buffalo (biological, other, drug)

Completed
  • Anaplastic Astrocytoma
  • +64 more
  • DEC-205/NY-ESO-1 Fusion Protein CDX-1401
  • +3 more
  • Buffalo, New York
    Roswell Park Cancer Institute
Oct 3, 2016

Mucosal Melanoma, Recurrent Melanoma, Stage IIIA Skin Melanoma Trial in Australia, United States (Carboplatin, Laboratory

Completed
Has Results
  • Mucosal Melanoma
  • +5 more
  • Birmingham, Alabama
  • +218 more
Sep 28, 2015

Recurrent Melanoma, Stage IA Skin Melanoma, Stage IB Skin Melanoma Trial in Portland (gp100:209-217(210M) Peptide Vaccine, HPV

Completed
  • Recurrent Melanoma
  • +9 more
  • gp100:209-217(210M) Peptide Vaccine
  • +2 more
  • Portland, Oregon
    Providence Portland Medical Center
Jan 23, 2015